On Friday, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was 8.66% up from the session before settling in for the closing price of $12.12. A 52-week range for AUPH has been $6.55 – $13.54.
When this article was written, the company’s average yearly earnings per share was at 1520.83%. With a float of $118.93 million, this company’s outstanding shares have now reached $132.67 million.
The extent of productivity of a business whose workforce counts for 130 workers is very important to gauge.
Aurinia Pharmaceuticals Inc (AUPH) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aurinia Pharmaceuticals Inc stocks. The insider ownership of Aurinia Pharmaceuticals Inc is 9.65%, while institutional ownership is 43.90%. The most recent insider transaction that took place on Aug 01 ’25, was worth 10,120,000. In this transaction Director of this company bought 1,000,000 shares at a rate of $10.12, taking the stock ownership to the 11,029,500 shares. Before that another transaction happened on Aug 05 ’25, when Company’s Director bought 200,000 for $11.68, making the entire transaction worth $2,336,000. This insider now owns 11,329,500 shares in total.
Aurinia Pharmaceuticals Inc (AUPH) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted 0.1 earnings per share (EPS) during the time that was better than consensus figure (set at 0.01) by 0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1520.83% per share during the next fiscal year.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Trading Performance Indicators
You can see what Aurinia Pharmaceuticals Inc (AUPH) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.63. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.66. Likewise, its price to free cash flow for the trailing twelve months is 18.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.43, a number that is poised to hit 0.16 in the next quarter and is forecasted to reach 0.76 in one year’s time.
Technical Analysis of Aurinia Pharmaceuticals Inc (AUPH)
The latest stats from [Aurinia Pharmaceuticals Inc, AUPH] show that its last 5-days average volume of 1.61 million was inferior to 1.62 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 71.32%.
During the past 100 days, Aurinia Pharmaceuticals Inc’s (AUPH) raw stochastic average was set at 94.08%, which indicates a significant decrease from 94.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.45 in the past 14 days, which was higher than the 0.45 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.08, while its 200-day Moving Average is $9.39. Now, the first resistance to watch is $13.63. This is followed by the second major resistance level at $14.08. The third major resistance level sits at $14.86. If the price goes on to break the first support level at $12.39, it is likely to go to the next support level at $11.61. The third support level lies at $11.16 if the price breaches the second support level.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Key Stats
There are 131,630K outstanding shares of the company, which has a market capitalization of 1.73 billion. As of now, sales total 235,130 K while income totals 5,750 K. Its latest quarter income was 70,010 K while its last quarter net income were 21,510 K.
